The FDA has approved Nucala (mepolizumab) as an add-on maintenance treatment for certain COPD patients whose disease isn't ...

Nucula’s new indication is as an add-on therapy for patients with COPD who also have an elevated blood eosinophil count.

GSK respiratory, immunology and inflammation research and development (R&D) global head and senior vice-president Kaivan ...

KIMSHEALTH Trivandrum restores oxygen levels in a Tamil Nadu woman through rare lung surgery to remove life-threatening blood ...

GSK plc GSK announced that the FDA has approved its blockbuster respiratory drug, Nucala (mepolizumab), for a fifth ...